602
Views
16
CrossRef citations to date
0
Altmetric
Drug Evaluation

MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis

, MD & , MD
Pages 1049-1058 | Published online: 01 Apr 2008

Bibliography

  • Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48(4):526-35
  • Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99(7):1371-85
  • Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940 – 1993: incidence, prevalence, and survival. Gut 2000;46(3):336-43
  • Ghosh S, Shand A, Ferguson A. Ulcerative colitis. BMJ 2000;320(7242):1119-23
  • Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;23(5):577-85
  • Lim WC, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord 2004;4(3):104-17
  • Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 2007;4(3):160-70
  • Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972;181(3):555-62
  • Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;2:CD000544
  • Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;2:CD000543
  • Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995;9(3):293-300
  • Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95(5):1263-76
  • Safdi M, Demicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92(10):1867-71
  • D'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997;92(7):1143-7
  • Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa® (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54(7):960-5
  • Piodi LP, Ulivieri FM, Cermesoni L, Cesana BM. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 2004;39(2):154-7
  • Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100(6):1345-53
  • Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin Drug Saf 2007;6(2):99-107
  • Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19(2):179-89
  • Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001;96(10):2929-33
  • Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(2):191-8
  • Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8(12):1179-83
  • Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114(1):39-43
  • Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007;102(7):1417-26
  • Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003;98(7):1535-44
  • Once-daily mesalamine (Lialda®) for ulcerative colitis. Med Lett Drugs Ther 2007;49(1257):25-6
  • Baker DE. MMX mesalamine. Rev Gastroenterol Disord 2006;6(3):146-52
  • Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005;11(5):421-7
  • Brunner M, Assandri R, Kletter K, et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003;17(3):395-402
  • Tenjarla S, Romasanta V, Zeijdner E, et al. Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Adv Ther 2007;24(4):826-40
  • MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol 2000;95(12):3343-5
  • Nikolaus S, Folscn U, Schreiber S. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 2000;47(31):71-82
  • Bantel H, Berg C, Vieth M, et al. Mesalazine inhibits activation of transcription factor NF-kappa B in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000;95(12):3452-7
  • Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005;201(8):1205-15
  • Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):10-4
  • Shire Pharmaceuticals, Inc. Lialda® prescribing information. Wayne, PA: Shire Pharmaceuticals; 2007
  • Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001;15(1):53-62
  • Corey AE, Rose GM, Conklin JD. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine. J Int Med Res 1990;18(6):441-53
  • Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17(1):29-42
  • Bondesen S. Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease. Pharmacol Toxicol 1997;81(Suppl 2):1-28
  • Zhou SY, Fleisher D, Pao LH, et al. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999;27(4):479-85
  • Lichtenstein GR, Sandborn WJ, Kamm MA, et al. MMX mesalamine, a novel formulation of 5-ASA, effectively induces the remission of active mild-to-moderate ulcerative colitis in men and women [abstract 1103]. American College of Gastroenterology Annual Scientific Meeting; Las Vegas, NV; October 2006
  • D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 2006;24(7):1087-97
  • Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132(1):66-75; quiz 432-33
  • Lichtenstein GR, Kamm MA, Boddu P et al.: Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5(1):95-102
  • Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX multi-matrix system mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007;26(2):205-15
  • Sandborn WJ, Karlstadt R, Barrett K, et al. Time to initial symptom resolution with MMX mesalamine therapy for active, mild-to-moderate ulcerative colitis [abstract 619]. American College of Gastroenterology Annual Scientific Meeting; Philadelphia, PA; October 2007
  • Lichtenstein GR, Kamm MA, Sandborn WJ, et al. Once- and twice-daily SPD476, a novel, high-strength formulation of 5-ASA, induces remission of both mild and moderate ulcerative colitis: a prespecified analysis of combined data from two pivotal, randomized, placebo-controlled, phase III studies [abstract T1147]. Digestive Disease Week; Los Angeles, CA; May 2006
  • Kamm MA, Lichtenstein GR, Sandborn WJ, et al. SPD476, a novel formulation of 5-ASA given once or twice daily, is effective for the induction of remission of left-sided and extensive ulcerative colitis: an analysis of combined data from two pivotal, randomized, placebo-controlled phase III studies [abstract T1148]. Digestive Disease Week; Los Angeles, CA; May 2006
  • Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa® Study Group. Am J Gastroenterol 1993;88(8):1188-97
  • Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005;100(11):2478-85
  • Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol®) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med 1991;115(5):350-5
  • Kamm MA, Colombel J, Kornbluth A, et al. A randomized comparison of once- versus twice-daily MMX mesalamine for the maintenance of remission in mild-to-moderate ulcerative colitis [abstract T1296]. Digestive Disease Week; Washington, DC; May 2007
  • Kamm MA, Hanauer SB, Lichtenstein GR, et al. MMX mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis: outcome in patients treated over 14 – 16 months [abstract T1297]. Digestive Disease Week; Washington, DC; May 2007
  • An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med 1996;124(2):204-11
  • Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa® UC Maintenance Study Group. Dig Dis Sci 1995;40(2):296-304
  • Panaccione R, Kamm MA, Karlstadt R, et al. Once- or twice-daily MMX mesalamine for the maintenance of remission of mild or moderate ulcerative colitis [abstract 950]. American College of Gastroenterology Annual Scientific Meeting; Philadelphia, PA; October 2007
  • Lichtenstein GR, Kamm MA, Karlstadt R, et al. MMX mesalamine is effective for the maintenance of ulcerative colitis remission in both left-sided and extensive disease [abstract 949]. American College of Gastroenterology Annual Scientific Meeting; Philadelphia, PA; October 2007
  • Lichtenstein GR, Diebold R, Karlstadt R, et al. The effect of sigmoidoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to-moderate ulcerative colitis [abstract T1284]. Digestive Disease Week; Washington, DC; May 2007
  • Lichtenstein GR, Kamm MA, Sandborn WJ, et al. MMX mesalamine is well tolerated in patients with active mild-to-moderate ulcerative colitis: pooled analysis of adverse events from three randomized studies [abstract 1104]. American College of Gastroenterology Annual Scientific Meeting; Las Vegas, NV; October 2006
  • Lichtenstein GR, Butler T, Barrett K, et al. MMX mesalamine for maintaining remission of ulcerative colitis: interim safety results [abstract 1106]. American College of Gastroenterology Annual Scientific Meeting; Las Vegas, NV; October 2006
  • Proctor & Gamble Pharmaceuticals, Inc. Asacol® prescribing information. Cincinnati, OH: Proctor & Gamble; 2006
  • Shire Pharmaceuticals, Inc. Pentasa® prescribing information. Wayne, PA: Shire Pharmaceuticals; 2007
  • Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003;1(3):170-3

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.